The problem of false-positive human papillomavirus DNA tests in cervical screening

Current Pharmaceutical Design

Volumn 19, Issue 8, 2013, Pages 1439-1449

  Rebolj, Matejka ^a   Pribac, Igor ^b   Frederiksen, Maria Eiholm ^a   Lynge, Elsebeth ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Cytology; DNA probes HPV; False positive reactions; Human papillomavirus; Mass screening; Triage; Uterine cervical neoplasms

Indexed keywords

ARTICLE; CANCER GRADING; COLPOSCOPY; CYTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; MASS SCREENING; PAPILLOMAVIRUS INFECTION; PATIENT CARE; PATIENT SAFETY; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

EID: 84876718744     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804805595     Document Type: Article

References (93)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9.
2. Helmerhorst TJ, Meijer CJ. Cervical cancer should be considered as a rare complication of oncogenic HPV infection rather than a STD. Int J Gynecol Cancer 2002; 12: 235-6.
3. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens--Part B: biological agents. Lancet Oncol 2009; 10: 321-2.
4. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278-85.
5. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 89-99.
6. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009; 2: 868-78.
7. Lynge E, Antilla A, Arbyn M, Segnan N, Ronco G. What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination. Eur J Cancer 2009; 45: 2714-21.
8. Soutter WP, de Barros LA, Fletcher A, et al. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet 1997; 349: 978-80.
9. Spence AR, Goggin P, Franco EL. Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev Med 2007; 45: 93-106.
10. Hakama M, Rasanen-Virtanen U. Effect of a mass screening program on the risk of cervical cancer. Am J Epidemiol 1976; 103: 512-7.
11. Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987; 1: 1247-9.
12. IARC. IARC Handbooks of Cancer Prevention, Vol. 10: Cervix cancer screening. Lyon: International Agency for Research on Cancer Press 2005.
13. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579-88.
14. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11: 249-57.
15. Anttila A, Kotaniemi-Talonen L, Leinonen M, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ 2010; 340: c1804.
16. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012; 13: 78-88.
17. Kitchener HC, Almonte M, Gilham C, et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess 2009; 13: 1-150.
18. Ogilvie GS, van Niekerk DJ, Krajden M, et al. A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). BMC Cancer 2010; 10: 111.
19. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-97.
20. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-94.
21. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008; 100: 492-501.
22. Leinonen M, Nieminen P, Kotaniemi-Talonen L, et al. Agespecific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009; 101: 1612-23.
23. Kitchener HC, Gilham C, Sargent A, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer 2011; 47: 864-71.
24. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: 969-72.
25. Schiffman M, Glass AG, Wentzensen N, et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev 2011; 20: 1398-409.
26. Berkhof J, Coupe VM, Bogaards JA, et al. The health and economic effects of HPV DNA screening in The Netherlands. Int J Cancer 2010; 127: 2147-58.
27. Rebolj M, Njor SH, Lynge E. Restriction of human papillomavirus DNA testing in primary cervical screening to women above age 30: systematic review. Eur J Cancer Prev 2012; 21: 73-81.
28. Lynge E, Rebolj M. Primary HPV screening for cervical cancer prevention: results from European trials. Nat Rev Clin Oncol 2009; 6: 699-706.
29. Kinney W, Stoler MH, Castle PE. Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol 2010; 134: 193-9.
30. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007;197: 356. e1-6.
31. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32(Suppl 1): S16-24.
32. Barken SS, Rebolj M, Sogaard AE, Lynge E. Frequency of cervical intraepithelial neoplasia treatment in a well-screened population. Int J Cancer 2012; 130: 2438-44.
33. Stoler MH, Castle PE, Solomon D, Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol 2007; 127: 335-7.
34. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012; 137: 516-42.
35. Snijders PJ, van den Brule AJ, Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 2003; 201: 1-6.
36. Szarewski A, Sasieni P. Cervical screening in adolescents--at least do no harm. Lancet 2004; 364: 1642-4.
37. Bell S, Porter M, Kitchener H, Fraser C, Fisher P, Mann E. Psychological response to cervical screening. Prev Med 1995; 24: 610-6.
38. Cullen J, Schwartz MD, Lawrence WF, Selby JV, Mandelblatt JS. Short-term impact of cancer prevention and screening activities on quality of life. J Clin Oncol 2004; 22: 943-52.
39. Drolet M, Brisson M, Maunsell E, et al. The psychosocial impact of an abnormal cervical smear result. Psychooncology (Epub ahead of print).
40. Gray NM, Sharp L, Cotton SC, et al. Psychological effects of a low-grade abnormal cervical smear test result: anxiety and associated factors. Br J Cancer 2006; 94: 1253-62.
41. Kitchener HC, Fletcher I, Roberts C, Wheeler P, Almonte M, Maguire P. The psychosocial impact of human papillomavirus testing in primary cervical screening-a study within a randomized trial. Int J Gynecol Cancer 2008; 18: 743-8.
42. Salz T, Gottlieb SL, Smith JS, Brewer NT. The association between cervical abnormalities and attitudes toward cervical cancer prevention. J Womens Health (Larchmt) 2010; 19: 2011-6.
43. Insinga RP, Glass AG, Myers ER, Rush BB. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making 2007; 27: 414-22.
44. Waller J, McCaffery K, Kitchener H, Nazroo J, Wardle J. Women's experiences of repeated HPV testing in the context of cervical cancer screening: a qualitative study. Psychooncology 2007; 16: 196-204.
45. Hellsten C, Lindqvist PG, Sjostrom K. A longitudinal study of sexual functioning in women referred for colposcopy: a 2-year follow up. BJOG 2008; 115: 205-11.
46. Hellsten C, Sjostrom K, Lindqvist PG. A 2-year follow-up study of anxiety and depression in women referred for colposcopy after an abnormal cervical smear. BJOG 2008; 115: 212-8.
47. Dietsch E, Davies C. The nocebo effect for women in waiting. Collegian 2007; 14: 9-14.
48. Frederiksen M, Lynge E, Rebolj M. What women want. Women's preferences for the management of low-grade abnormal cervical screening tests: a systematic review. BJOG 2011; 119: 7-19.
49. Kitchener HC, Burns S, Nelson L, et al. A randomised controlled trial of cytological surveillance versus patient choice between surveillance and colposcopy in managing mildly abnormal cervical smears. BJOG 2004; 111: 63-70.
50. Maissi E, Marteau TM, Hankins M, Moss S, Legood R, Gray A. The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 6-month follow-up. Br J Cancer 2005; 92: 990-4.
51. Jones MH, Singer A, Jenkins D. The mildly abnormal cervical smear: patient anxiety and choice of management. J R Soc Med 1996; 89: 257-60.
52. Peters T, Somerset M, Baxter K, Wilkinson C. Anxiety among women with mild dyskaryosis: a randomized trial of an educational intervention. Br J Gen Pract 1999; 49: 348-52.
53. Meana M, Stewart DE, Lickrish GM, Murphy J, Rosen B. Patient preference for the management of mildly abnormal Papanicolaou smears. J Womens Health Gend Based Med 1999; 8: 941-7.
54. McCaffery KJ, Irwig L, Chan SF, et al. HPV testing versus repeat Pap testing for the management of a minor abnormal Pap smear: evaluation of a decision aid to support informed choice. Patient Educ Couns 2008; 73: 473-81.
55. Basen-Engquist K, Fouladi RT, Cantor SB, et al. Patient assessment of tests to detect cervical cancer. Int J Technol Assess Health Care 2007; 23: 240-7.
56. Freeman-Wang T, Walker P, Linehan J, Coffey C, Glasser B, Sherr L. Anxiety levels in women attending colposcopy clinics for treatment for cervical intraepithelial neoplasia: a randomised trial of written and video information. BJOG 2001; 108: 482-4.
57. Byrom J, Clarke T, Neale J, et al. Can pre-colposcopy sessions reduce anxiety at the time of colposcopy? A prospective randomised study. J Obstet Gynaecol 2002; 22: 415-20.
58. Howells RE, Dunn PD, Isasi T, et al. Is the provision of information leaflets before colposcopy beneficial? A prospective randomised study. Br J Obstet Gynaecol 1999; 106: 528-34.
59. de Bie RP, Massuger LF, Lenselink CH, Derksen YH, Prins JB, Bekkers RL. The role of individually targeted information to reduce anxiety before colposcopy: a randomised controlled trial. BJOG 2011; 118: 945-50.
60. Sawaya GF, Grimes DA. New technologies in cervical cytology screening: a word of caution. Obstet Gynecol 1999; 94: 307-10.
61. van Agt HM, Fracheboud J, Rebolj M, Korfage IJ, de Koning HJ. Volledige, evenwichtige en eerlijke voorlichting over nut en risico's van bevolkingsonderzoek naar kanker [Complete, balanced and honest information regarding the benefits and risks of screening for cancer]. Rotterdam: Erasmus MC, Department of Public Health 2008.
62. Woolf SH, Harris R. The harms of screening: new attention to an old concern. JAMA 2012; 307: 565-566.
63. Fiebig DG, Haas M, Hossain I, Street DJ, Viney R. Decisions about Pap tests: what influences women and providers? Soc Sci Med 2009; 68: 1766-74.
64. Naucler P, Ryd W, Tornberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009; 101: 88-99.
65. Katki HA, Wentzensen N. How might HPV testing be integrated into cervical screening? Lancet Oncol 2012; 13: 8-10.
66. Last JM, Ed. A dictionary of epidemiology. 4th ed. Oxford: Oxford University Press 2001.
67. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006; 7: 547-55.
68. Rebolj M, Pribac I, Lynge E. False-positive Human Papillomavirus DNA tests in cervical screening: It is all in a definition. Eur J Cancer 2011; 47: 255-61.
69. Ronco G, Segnan N, Giorgi-Rossi P, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006; 98: 765-74.
70. Rebolj M, Bonde J, Njor SH, Lynge E. Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review. BMJ 2011; 342: d2757.
71. Rebolj M, Lynge E. Incomplete follow-up of positive HPV tests: overview of randomised controlled trials on primary cervical screening. Br J Cancer 2010; 103: 310-4.
72. Kotaniemi-Talonen L, Malila N, Nieminen P, et al. Test positivity cutoff level of a high risk human papillomavirus test could be increased in routine cervical cancer screening. Int J Cancer 2008; 123: 2902-6.
73. Davey E, Barratt A, Irwig L, et al. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 2006; 367: 122-32.
74. Carozzi F, Confortini M, Dalla Palma P, et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2008; 9: 937-45.
75. Sargent A, Bailey A, Turner A, et al. Optimal Threshold for a Positive Hybrid Capture 2 Test for Detection of Human Papillomavirus: Data from the ARTISTIC Trial. J Clin Microbiol 2010; 48: 554-8.
76. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009; 124: 516-20.
77. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12: 186-92.
78. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9: 425-34.
79. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003; 362: 1871-6.
80. Moy LM, Zhao FH, Li LY, et al. Human papillomavirus testing and cervical cytology in primary screening for cervical cancer among women in rural China: comparison of sensitivity, specificity, and frequency of referral. Int J Cancer 2010; 127: 646-56.
81. Rijkaart DC, Coupe VM, van Kemenade FJ, et al. Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test. Br J Cancer 2010; 103: 939-46.
82. Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001; 84: 1616-23.
83. Nieminen P, Vuorma S, Viikki M, Hakama M, Anttila A. Comparison of HPV test versus conventional and automationassisted Pap screening as potential screening tools for preventing cervical cancer. BJOG 2004; 111: 842-8.
84. Sasieni P, Castanon A. Safe thresholds for hybrid capture 2 test in primary cervical screening. BMJ 2011; 342: d2941.
85. Cuschieri K. Human Papillomavirus testing: the challenges of picking the right tools for the job. Expert Rev Obstet Gynecol 2011; 6: 643-53.
86. Monsonego J, Hudgens MG, Zerat L, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquidbased cytology in primary cervical cancer screening: The FASE study. Int J Cancer 2010; 129: 691-701.
87. Korfage IJ, van Ballegooijen M, Wauben B, Habbema JD, Essink-Bot ML. Informed choice on Pap smear still limited by lack of knowledge on the meaning of false-positive or false-negative test results. Patient Educ Couns 2011; 85: 214-8.
88. Raffle AE. Information about screening-is it to achieve high uptake or to ensure informed choice? Health Expect 2001; 4: 92-8.
89. Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006; 24(Suppl 3): S3/171-7.
90. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011; 12: 663-72.
91. Health Council of the Netherlands. Screening op baarmoederhalskanker [Cervical cancer screening]. Publicatienr. 2011/07. Den Haag: Gezondheidsraad 2011.
92. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-72.
93. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009; 10: 672-82.